# Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus

> **NCT06085378** · NA · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 630 (estimated)

## Conditions studied

- Acute Ischemic Stroke
- Type 2 Diabetes

## Interventions

- **DRUG:** Urinary Kallidinogenase for injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06085378
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 630 (ESTIMATED)
- **Last updated:** 2023-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06085378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06085378, "Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06085378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*